Boston Scientific Adds Hydrogel to Blood-Blocking Portfolio

In a bid to thicken its blood-blocking solutions pipeline, Boston Scientific is harkening back to its hot-streak M&A trend from last year to acquire South Carolina-based embolization technology company Obsidio. Its hydrogel tech, which earned FDA clearance last month, can produce a blockade in an individual’s blood vessels...